Loading...
XHKG
0954
Market cap19mUSD
Dec 03, Last price  
0.28HKD
1D
-3.45%
1Q
-9.68%
Jan 2017
-75.00%
IPO
-62.16%
Name

Changmao Biochemical Engineering Co Ltd

Chart & Performance

D1W1MN
XHKG:0954 chart
P/E
P/S
0.23
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
3.41%
Revenues
585m
-8.21%
93,041,986321,440,000397,420,000418,426,000385,302,000515,574,000620,233,000653,218,000703,032,000561,669,000514,779,000594,402,000630,841,000639,120,000494,580,000444,106,000547,976,000730,034,000637,078,000584,794,000
Net income
-68m
L-20.70%
34,973,36967,358,00034,648,00045,929,00043,203,00075,773,00041,105,00049,455,00069,992,00037,223,00045,274,00033,172,0003,382,00050,525,00058,299,00016,827,00058,318,00081,423,000-86,057,000-68,243,000
CFO
-32m
L+1,275.78%
25,519,58863,716,00019,802,00074,378,00087,674,00057,081,00044,543,00093,619,00068,584,00097,393,00071,919,00049,132,00065,781,00044,478,000118,327,00058,905,000-6,939,00019,633,000-2,349,000-32,317,000
Dividend
May 22, 20230.086829 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally. Its products include fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame that are used as food additives, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. The company is also involved in the research and development of medicine and nutraceutical products; production and sale of food additives; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou, the People's Republic of China.
IPO date
Jun 28, 2002
Employees
574
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT